<description>&lt;p&gt;In this episode, recorded on-site at the ASGCT 2026 Annual Meeting, &lt;em&gt;Molecular Therapy Advances&lt;/em&gt; Associate Editor-in-Chief Dr. Dan Stone speaks with Dr. Dan DuBreuil of Sanofi. They break down the science behind a recent paper detailing the development of a secretable frataxin, highlighting its potential to improve treatment efficacy for Friedreich&amp;rsquo;s ataxia.&lt;/p&gt; &lt;p&gt;&lt;strong&gt;Music:&lt;/strong&gt;&amp;nbsp;'Electric Dreams' by Scott Buckley - released under CC-BY 4.0.&amp;nbsp;&lt;a href="https://www.scottbuckley.com.au/"&gt;www.scottbuckley.com.au&lt;/a&gt;&lt;/p&gt;&lt;p&gt;&lt;a href="https://asgct.org/membership/donate" rel="payment"&gt;Show your support for ASGCT!: https://asgct.org/membership/donate&lt;/a&gt;&lt;/p&gt;&lt;p&gt;See &lt;a href="https://omnystudio.com/listener"&gt;omnystudio.com/listener&lt;/a&gt; for privacy information.&lt;/p&gt;</description>

ASGCT Podcast Network

American Society of Gene & Cell Therapy

Development of a secretable frataxin for Friedrich’s ataxia with Dr. Dan DuBreuil

JUN 4, 202619 MIN
ASGCT Podcast Network

Development of a secretable frataxin for Friedrich’s ataxia with Dr. Dan DuBreuil

JUN 4, 202619 MIN

Description

In this episode, recorded on-site at the ASGCT 2026 Annual Meeting, Molecular Therapy Advances Associate Editor-in-Chief Dr. Dan Stone speaks with Dr. Dan DuBreuil of Sanofi. They break down the science behind a recent paper detailing the development of a secretable frataxin, highlighting its potential to improve treatment efficacy for Friedreich’s ataxia. Music: 'Electric Dreams' by Scott Buckley - released under CC-BY 4.0. www.scottbuckley.com.auShow your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.